Avalyn Pharma (NASDAQ:AVLN) Stock Price Up 6.5% on Analyst Upgrade

Shares of Avalyn Pharma Inc. (NASDAQ:AVLN) rose 6.5% on Thursday after Zacks Research upgraded the stock to a hold rating. The stock traded as high as $28.59 and last traded at $28.57. Approximately 8,663 shares traded hands during mid-day trading, a decline of 97% from the average daily volume of 345,549 shares. The stock had previously closed at $26.82.

Other research analysts also recently issued reports about the company. Evercore started coverage on Avalyn Pharma in a report on Tuesday. They issued an “outperform” rating and a $51.00 price target for the company. Morgan Stanley started coverage on Avalyn Pharma in a report on Tuesday. They issued an “overweight” rating and a $53.00 price target for the company. Jefferies Financial Group started coverage on Avalyn Pharma in a report on Monday. They issued a “buy” rating and a $52.00 price target for the company. Guggenheim started coverage on Avalyn Pharma in a report on Monday. They issued a “buy” rating and a $80.00 price target for the company. Finally, Wall Street Zen upgraded Avalyn Pharma to a “hold” rating in a report on Saturday, May 9th. Two analysts have rated the stock with a Strong Buy rating, two have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Avalyn Pharma currently has a consensus rating of “Buy” and a consensus target price of $59.00.

Insider Transactions at Avalyn Pharma

In related news, Director Jill Carroll acquired 277,778 shares of the company’s stock in a transaction dated Friday, May 1st. The stock was bought at an average price of $18.00 per share, with a total value of $5,000,004.00. Following the purchase, the director directly owned 2,186,562 shares in the company, valued at $39,358,116. The trade was a 14.55% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Sr One Capital Management, Llc acquired 555,555 shares of the company’s stock in a transaction dated Friday, May 1st. The shares were bought at an average cost of $18.00 per share, with a total value of $9,999,990.00. Following the purchase, the insider owned 2,186,562 shares in the company, valued at approximately $39,358,116. The trade was a 34.06% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

Avalyn Pharma Price Performance

Avalyn Pharma Company Profile

We are a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare respiratory diseases with significant unmet needs. Our approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs to enhance efficacy and minimize systemic exposure that contributes to side effects and treatment discontinuation. Our current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer.